SCHEMBL23979449

SCHEMBL23979449

Cc1nc2cc(Cl)ccc2c(=O)n1C1CCCC(=O)NC1=O

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 12/20 0.62
DDB1 Q16531 11/20 0.62
TNF P01375 1/20 0.50
IL1B P01584 1/20 0.50
IKZF3 Q9UKT9 1/20 0.50
KCNH2 Q12809 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
KMT2A Q03164 2/20 0.42
PLA2G1B P04054 1/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ATG4B Q9Y4P1 1/20 0.41
GAA P10253 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP1A1 P04798 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP1B1 Q16678 1/20 0.39
MEN1 O00255 1/20 0.36
MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3651039 0.93 CRBN (0.71) CRBNDDB1TNFIL1BIKZF3
SCHEMBL23979411 0.89 CRBN (0.65) CRBNDDB1TNFIL1BIKZF3
SCHEMBL23979390 0.87 CRBN (0.62) CRBNDDB1TNFIL1BIKZF3
SCHEMBL23979591 0.87 CRBN (0.62) CRBNDDB1TNFIL1BIKZF3
SCHEMBL23979423 0.87 CRBN (0.62) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3655019 0.84 DDB1 (0.71) CRBNDDB1TNFIL1BIKZF3
SCHEMBL23979400 0.84 CRBN (0.59) CRBNDDB1TNFIL1BIKZF3
SCHEMBL23979394 0.84 DDB1 (0.59) CRBNDDB1TNFIL1BIKZF3
SCHEMBL23979477 0.83 DDB1 (0.67) CRBNDDB1TNFIL1BIKZF3
SCHEMBL3653462 0.82 CRBN (0.74) CRBNDDB1TNFIL1BIKZF3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same SALARIUS PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME SALARIUS PHARMACEUTICALS, INC. 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same HPGDS, HPGD, AQP3 CRBN 1079/4885DDB1 690/4885TNF 2820/4885
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME HPGDS, HPGD, AQP3 CRBN 1079/4885DDB1 690/4885TNF 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.